The following immunotherapy is approved as first treatment:
- Atezolizumab (Tecentriq, a PD-L1 inhibitor) in combination with chemotherapy
The following immunotherapies are approved as a 3rd treatment (after two other treatments are no longer working):
- Opdivo (nivolumab, a PD-1 inhibitor)
- Keytruda (pembrolizumab, a PD-1 inhibitor)
Click here for answers to frequently asked questions about immunotherapy for lung cancer.